Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Dec;42(12):5512-6.
doi: 10.1128/JCM.42.12.5512-5516.2004.

Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates from India and Mexico by a molecular beacon assay

Affiliations
Comparative Study

Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates from India and Mexico by a molecular beacon assay

Mandira Varma-Basil et al. J Clin Microbiol. 2004 Dec.

Abstract

We assessed the performance of a rapid, single-well, real-time PCR assay for the detection of rifampin-resistant Mycobacterium tuberculosis by using clinical isolates from north India and Mexico, regions with a high incidence of tuberculosis. The assay uses five differently colored molecular beacons to determine if a short region of the M. tuberculosis rpoB gene contains mutations that predict rifampin resistance in most isolates. Until now, the assay had not been sufficiently tested on samples from countries with a high incidence of tuberculosis. In the present study, the assay detected mutations in 16 out of 16 rifampin-resistant isolates from north India (100%) and in 55 of 64 rifampin-resistant isolates from Mexico (86%) compared to results with standard susceptibility testing. The assay did not detect mutations (a finding predictive of rifampin susceptibility) in 37 out of 37 rifampin-susceptible isolates from India (100%) and 125 out of 126 rifampin-susceptible isolates from Mexico (99%). DNA sequencing revealed that none of the nine rifampin-resistant isolates from Mexico, which were misidentified as rifampin susceptible by the molecular beacon assay, contained a mutation in the region targeted by the molecular beacons. The one rifampin-susceptible isolate from Mexico that appeared to be rifampin resistant by the molecular beacon assay contained an S531W mutation, which is usually associated with rifampin resistance. Of the rifampin-resistant isolates that were correctly identified in the molecular beacon assay, one contained a novel L530A mutation and another contained a novel deletion between codons 511 and 514. Overall, the molecular beacon assay appears to have sufficient sensitivity (89%) and specificity (99%) for use in countries with a high prevalence of tuberculosis.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Typical real-time PCR results for selected rifampin-susceptible and rifampin-resistant M. tuberculosis isolates. (A) A rifampin-susceptible isolate in which all five differently colored molecular beacons hybridized to the rpoB core region. (B to E) Rifampin-resistant isolates in which either (B) probe A, (C) probe B, (D) probe D, or (E) probe E failed to fluoresce. None of the isolates had a flat signal for probe C. The fluorescence of each molecular beacon is indicated as follows: ○, probe A; ▵, probe B; ▪, probe C; ▴, probe D; and ⋄, probe E.
FIG. 2.
FIG. 2.
Detection of double mutations or deletions. No fluorescence increase was observed for two differently colored probes in three of the isolates, suggesting the presence of multiple mutations. (A) Probes A and D failed to fluoresce; (B) probes B and E failed to fluoresce; and (C) probes and A and B failed to fluoresce. The fluorescence of each molecular beacon is indicated as follows: ○, probe A; ▴, probe B; ▪, probe C; ⋄, probe D; and ▵, probe E.

Similar articles

Cited by

References

    1. Alland, D., G. E. Kalkut, A. R. Moss, R. A. McAdam, J. A. Hahn, W. Boswoth, E. Drucker, and B. R. Bloom. 1994. Transmission of tuberculosis in New York City, an analysis by DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med. 330:1710-1716. - PubMed
    1. Bobadilla, M., A. Ponce-de-Leon, C. Arenas-Huertero, G. Vargas-Alarcon, M. Kato-Maeda, P. M. Small, P. Couary, G. M. Ruiz-Palacios, and J. Sifuentes-Osornio. 2001. rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-strand conformational polymorphism. Emerg. Infect. Dis. 7:1010-1013. - PMC - PubMed
    1. De Beenhouwer, H., Z. Lhiang, G. Jannes, W. Mijs, L. Machtelinckx, R. Rossau, H. Traore, and F. Portaels. 1995. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber. Lung Dis. 76:425-430. - PubMed
    1. El-Hajj, H., S. A. E. Marras, S. Tyagi, F. R. Kramer, and D. Alland. 2001. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J. Clin. Microbiol. 39:4131-4137. - PMC - PubMed
    1. Frieden, T. R., L. F. Sherman, K. L. Maw, P. I. Fujiwara, J. T. Crawford, B. Nivin, V. Sharp, D. Hewlett, K. Brudney, D. Alland, and B. N. Kreiswirth. 1996. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 276:1229-1235. - PubMed

Publication types

MeSH terms